CG Oncology, Inc. 8-K

What Happened

• CG Oncology, Inc. (CGON) filed an 8-K disclosing that on May 20, 2026 the company and Ambaw Bellete, its President & Chief Operating Officer, agreed that Mr. Bellete will separate from the company effective June 30, 2026. The company stated it expects to enter a separation agreement providing a general release and the severance benefits described in Section 4(b) of Mr. Bellete’s Amended and Restated Employment Agreement (effective January 9, 2025), which was filed as Exhibit 10.12 to the company’s 2024 Form 10-K.
• On the same date (May 20, 2026), the Board approved appointment of Arthur Kuan as President of the company in addition to his existing roles. The filing references Mr. Kuan’s biography as included in CG Oncology’s definitive proxy statement on Schedule 14A filed April 24, 2026. The company has initiated a search for a Chief Commercial Officer.

Key Details

• Separation agreement effective date: June 30, 2026 (as agreed May 20, 2026).
• Severance: Mr. Bellete will receive the severance benefits set forth in Section 4(b) of his Amended and Restated Employment Agreement (effective Jan 9, 2025; filed as Exhibit 10.12 to 2024 Form 10‑K).
• Board action date: May 20, 2026 — approved Arthur Kuan’s appointment as President.
• Company has begun a search to fill a Chief Commercial Officer role.

Why It Matters

• This 8-K reports a leadership change at the President/COO level that may affect CG Oncology’s commercial leadership and ongoing operations during the transition. The company has named an internal executive (Arthur Kuan) as President and is actively searching for a Chief Commercial Officer, while the departing executive will receive contractual severance per the company’s prior employment agreement. Investors should note the change in senior commercial leadership and monitor subsequent disclosures about the CCO search and any material terms of the separation agreement.